PD-1 and LAG-3 synergize to drive tumor-infiltration of T cytotoxic cells in NSCLC tumors Read more about PD-1 and LAG-3 synergize to drive tumor-infiltration of T cytotoxic cells in NSCLC tumors
Comparison of PD-L1 expression in primary and metastatic lung cancer biopsies Read more about Comparison of PD-L1 expression in primary and metastatic lung cancer biopsies
Analysis of Real-World PD-L1 Testing and PD-L1 IHC 28-8 and 22C3 Assay Concordance in Patients with Breast Cancer Read more about Analysis of Real-World PD-L1 Testing and PD-L1 IHC 28-8 and 22C3 Assay Concordance in Patients with Breast Cancer
Spatial analytics of the tumor microenvironment on double stained immunohistochemistry images using deep learning Read more about Spatial analytics of the tumor microenvironment on double stained immunohistochemistry images using deep learning
Sensitive detection of ctDNA in early-stage non-small cell lung cancer patients with a personalized sequencing assay Read more about Sensitive detection of ctDNA in early-stage non-small cell lung cancer patients with a personalized sequencing assay
Role of circulating tumor DNA (ctDNA) from Liquid Biopsy in Early Stage NSCLC Resected Lung Tumor Investigation (LIBERTI) Read more about Role of circulating tumor DNA (ctDNA) from Liquid Biopsy in Early Stage NSCLC Resected Lung Tumor Investigation (LIBERTI)
Reduction of tumor-infiltrating B cells linked to recurrence of NSCLC tumors Read more about Reduction of tumor-infiltrating B cells linked to recurrence of NSCLC tumors
Profiling exhausted T cells using Vectra® Polaris™multiplex immunofluorescence assay in HNSCC Read more about Profiling exhausted T cells using Vectra® Polaris™multiplex immunofluorescence assay in HNSCC
Distinguishing dendritic cell subtypes in the tumor microenvironment using MultiOmyxTM Read more about Distinguishing dendritic cell subtypes in the tumor microenvironment using MultiOmyxTM
Analytical development of the RaDaRTM assay, a highly sensitive and specific assay for the monitoring of minimal residual disease Read more about Analytical development of the RaDaRTM assay, a highly sensitive and specific assay for the monitoring of minimal residual disease